Pancreatic NET · 17 regimens
Cost vs Efficacy · 6 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Lutetium Lu 177 dotatate and Octreotide LAR Variant #02 | — | R 83 977 | 56d | ~22.8 mo | ~48.0 mo | ~13 | ~R 1 091 695 PFS proxy · indirect | 3 |
Temozolomide and Bevacizumab Variant #01 | — | R 42 823 | 28d | — | — | — | — | — |
Everolimus and Octreotide Variant #01 | — | R 37 172 | 28d | ~16.4 mo | — | ~18 | ~R 669 096 PFS proxy · indirect | 1 |
Sunitinib monotherapy Variant #05 | — | R 33 433 | 28d | ~12.6 mo | ~38.6 mo | ~14 | ~R 468 063 PFS proxy · indirect | 2 |
Lanreotide Depot/Autogel monotherapy Variant #01 | — | R 28 667 | 28d | — | — | — | — | 1 |
Octreotide LAR monotherapy Variant #01 | — | R 27 992 | 28d | ~8.5 mo | ~36.3 mo | ~10 | ~R 279 922 PFS proxy · indirect | 3 |
Temozolomide and Thalidomide Variant #01 | — | R 26 466 | 28d | — | — | — | — | — |
Everolimus monotherapy Variant #01 | — | R 18 360 | 28d | ~11.0 mo | ~44.0 mo | ~12 | ~R 220 316 PFS proxy · indirect | 2 |
Temozolomide monotherapy Variant #13 | — | R 8 153 | 28d | ~4.0 mo | ~16.3 mo | ~5 | ~R 40 764 PFS proxy · indirect | 10 |
Octreotide and Interferon alfa Variant #01 | — | R 7 732 | 7d | — | — | — | — | — |
Octreotide monotherapy Variant #04 | — | R 5 799 | — | — | — | — | — | — |
Capecitabine and Temozolomide Variant #01 | — | R 5 399 | 28d | — | — | — | — | — |
Lanreotide and Interferon alfa-2b Variant #01 | — | R 5 017 | 7d | — | — | — | — | — |
Doxorubicin and Streptozocin Variant #01 Partial | — | R 958 | 42d | — | — | — | — | — |
FAS Variant #01 Partial | — | R 658 | 28d | — | — | — | — | — |
Fluorouracil and Streptozocin Variant #01 Partial | — | R 275 | 42d | — | ~24.3 mo | — | — | — |
Placebo Partial | — | — | — | 4.4 mo | — | — | — | 3 |
17 of 17 regimens shown